Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-27
2010-02-16
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S279000, C544S292000, C544S105000, C544S284000, C514S230500, C546S242000, C549S341000
Reexamination Certificate
active
07662828
ABSTRACT:
Substituted 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl and 5,6,7,8-tetrahydro-quinazolin-2-yl compounds, corresponding to formula Iprocesses for the production thereof, pharmaceutical preparations containing these compounds the use thereof for the production of pharmaceutical preparations and related method of treating or inhibiting certain disorders or conditions, including pain.
REFERENCES:
patent: 2007/0135459 (2007-06-01), Dewdney et al.
patent: 0 436 157 (1991-07-01), None
patent: WO 99/21857 (1999-05-01), None
patent: WO 01/32659 (2001-05-01), None
patent: WO 01/44246 (2001-06-01), None
patent: WO 02/096422 (2002-12-01), None
patent: WO 03/068771 (2003-08-01), None
patent: WO 2004/016596 (2004-02-01), None
patent: WO 2004/022542 (2004-03-01), None
Pau, et al., Postgrad. Med. J. 2000; 76:299-306.
Urban, et al., Neuropharmacology, vol. 44, # 8, Jun. 2003, pp. 983-993.
Jaeschke, et al., Expert Opin. Ther. Patents (2009) 18(2), 123-142.
Pridmore, et al., Austral. & New Zeal. J. of Psych., 2004; 38:219-225.
Goethels, et al., Am. J. Psych. 2004;161:1916-1918.
Balschun, et al., Neuroscience, vol. 142, # 3, Oct. 27, 2006, 691-702.
Chen, Doctoral Dissertation, Vanderbilt Univ., Dec. 2007, 154 pages.
Wu, et al., Neuroscience Ltrs., vol. 307, # 3, Jul. 20, 2001, pp. 183-186.
Liebich, et al., J. Chromatog. A, vol. 843, Issues 1-2, May 28, 1999, pp. 237-245.
Sakai, et al., Applied & Environmental Microbiol., Jul. 1996, p. 2669-2672.
Broos, et al., J. Chem. Soc. Perkin Trans., 1995, 2899-2905.
Gennaro, Alfonso (Ed.),Reminaton's Pharmaceutical Sciences, 1985, Mack Publishing Company, Easton, PA, USA, Part 8 (King, Robert E., Ph.D.) pp. 1409-1680, Table of Contents Only.
Gray, E.G., et al., The Isolation of Nerve Endings From Brain: An Electron-Microscopic Study of Cell Fragments Derived by Homogenization and Centrifugation, Agricultural Research Council Institute of Animal Physiology, Journal of Anatomy, vol. 96, Part 1, pp. 79-96, Babraham, Cambridge.
Lowry, Oliver H., et al., “Protein Measurement With the Folin Phenol Reagent,” Department of Pharmacology, Washington University School of Medicine, St. , pp. 265-275, Louis, Missouri, May 28, 1951.
Frink, Martin Ch., et al., “Influence of Tramadol on Neurotransmitter Systems of the Rat Brain,” Arzneim.-Forsch./Drug Res. 46 (II), Nr. 11 (1996), pp. 1029-1036.
German Search Report dated Feb. 14, 2005 w/English translation (Eight (8) pages).
International Search Report dated 07/11/2005 (Three (3) pages).
Z. Magalas et al., “The serotonin
oradrenaline reuptake inhibitor venlifaxine attenuates acquisition, but not maintenance of intravenous self-administration of heroin in rats,”Europ. J. of Pharmacology528:103-09 (2005).
D. Mochizucki, “Serotonin and Noradrenaline Reuptake Inhibitors in Animal Models of Pain,”Human Psychopharmacology: Clinical and Experimental19:s15-s19 (2004).
K.-T Lu et al., “Endogenous Serotonin Inhibits Epileptiform Activity in Rat Hippocampal CA1 Neurons Via 5-Hydroxytryptamine 1A Receptor Activation”,Neuroscience3 (8): 729-37 (1998).
A. Erdinc et al., “The Efficacy of Venlafaxine in the Treatment of Women with Stress Urinary Incontinence,”Arch. Gynecol. Obstet. DOI 10.1007/s00404-008-0729-x (published online) Springer Verlag (2008).
Bijsterveld Edward
Haurand Michael
Hennies Hagen-Heinrich
Oberbörsch Stefan
Sundermann Bernd
Berch Mark L
Crowell & Moring LLP
Gruenenthal GmbH
Jaisle Cecilia M
LandOfFree
Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4173647